Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder
A legfontosabb adatok
- Ki végzi
- University Hospitals Cleveland Medical Center
- Hol
- Cleveland (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 100 fő, tervezett
- Kezdés
- 2019. márc. 27.
- Várható befejezés
- 2027. ápr. 1.
- A vizsgálat típusa
- Megfigyeléses, 5 csoport
- A vizsgált kezelések
- Eye tracking
- A regiszteradat frissítve
- 2026. október 9.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat bipoláris zavarral élő felnőtteket keres, szorongásos vagy szerhasználati zavarral vagy anélkül, valamint egészséges önkénteseket. Szemkövetéssel vizsgálják a figyelmet, a jutalomérzékenységet és a gondolkodás irányítását.
- Életkor
- 18 éves vagy idősebb
- Nem
- Férfiak és nők
- A betegség stádiuma
- I-es vagy II-es típusú bipoláris zavar, jelenleg depressziós epizódban vagy hangulati epizódból való remisszióban. Young mániaskála pontszám legfeljebb 8. Négy csoport: nincs szorongásos vagy szerhasználati zavar; szorongásos zavar (Hamilton-szorongásskála pontszám legalább 18); szorongás és szerhasználati zavar együtt; szerhasználati zavar szorongás nélkül (Hamilton-szorongásskála pontszám legfeljebb 12).
- Korábbi kezelés
- A pszichiátriai gyógyszereket a vizsgáló döntése szerint kell szednie. Az elmúlt 6 hónapban nem lehetett elektrokonvulzív terápiája (ECT) (a bipoláris csoportokban).
A részvétel fő kizáró okai
- Jelentős szerkezeti agyi elváltozás vagy előrehaladó idegrendszeri betegség
- Jelenleg terhes vagy terhességet tervez
- Jelenlegi antiszociális vagy borderline személyiségzavar (bipoláris csoportok); OCD, PTSD vagy ADHD a szorongásos csoportokban
- Szteroid, stimuláns vagy opioid fájdalomcsillapító szedése (egyes csoportokban)
- Nikotinhasználati zavar vagy bármilyen nikotinhasználat a szemkövetéses vizit előtti egy héten belül
A regiszter feltételei, szó szerint
Mind a 5 feltétel megnézéseKevesebb
Egyéb feltételek
- Inclusion and Exclusion Criteria for Group 1: bipolar disorder without current anxiety or substance use disorder; Inclusion Criteria for Group 1:; Male or female, age 18 or older; Meets diagnostic criteria for lifetime bipolar I or II disorder according to Diagnostic and Statistical Manual-5 (DSM-5) criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI); Currently in a depressive episode or currently in remission from a mood episode; Young Mania Rating Scale total score ≤ 8; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Subject is compliant with taking psychiatric medication(s) per the investigator's discretion; Exclusion Criteria for Group 1:; Significant structural brain lesion (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any current psychiatric disorder (other than a current depressive episode) including anxiety disorders, substance use disorders, antisocial personality disorder and borderline personality disorder as assessed by the MINI and clinician assessment; Currently pregnant or planning to become pregnant; Tests positive for illegal substances or prescription medications for which they do not have a valid prescription; Currently taking any steroids, stimulants, or opioid pain killers; Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine.Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit; Has had electroconvulsive therapy (ECT) treatment within the last 6 months
- Inclusion and Exclusion Criteria for Group 2: Bipolar disorder with a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia); Inclusion Criteria for Group 2:; Male or female, age 18 or older; Meets diagnostic criteria for lifetime bipolar I or II disorder according to DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI); Currently in a depressive episode or currently in remission from a mood episode; Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI); Hamilton Anxiety Rating Scale total score ≥ 18; Young Mania Rating Scale total score ≤ 8; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Subject is compliant with taking psychiatric medication(s) per the investigator's discretion; Exclusion Criteria for Group 2:; Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD); Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment; Currently pregnant or planning to become pregnant; Tests positive for illegal substances or prescription medications for which they do not have a valid prescription; Currently taking any steroids, stimulants, or opioid pain killers; Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine; Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit; Has had ECT treatment within the last 6 months
- Inclusion and Exclusion Criteria for Group 3: Bipolar disorder with a current anxiety disorder and a current substance use disorder; Inclusion Criteria for Group 3:; Male or female, age 18 or older; Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI); Meets diagnostic criteria for a substance use disorder within the last 3 months; Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI); Currently in a depressive episode or currently in remission from a mood episode; Hamilton Anxiety Rating Scale total score ≥ 18; Young Mania Rating Scale total score ≤ 8; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Subject is compliant with taking psychiatric medication(s) per the investigator's discretion; Exclusion Criteria for Group 3:; Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD); Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment; Intoxicated or in acute withdrawal state; Currently pregnant or planning to become pregnant; Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit; Has had ECT treatment within the last 6 months
- Inclusion and Exclusion Criteria for Group 4: Bipolar disorder without an anxiety disorder but with a current substance use disorder; Inclusion Criteria for Group 4:; Male or female, age 18 or older; Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI); Meets diagnostic criteria for a substance use disorder within the last 3 months; Currently in a depressive episode or currently in remission from a mood episode; Young Mania Rating Scale total score ≤ 8; Hamilton Anxiety Rating Scale total score ≤ 12; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Subject is compliant with taking psychiatric medication(s) per the investigator's discretion; Exclusion Criteria for Group 4:; Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any co-occurring current anxiety disorder or attention deficit hyperactivity disorder (ADHD); Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment; Intoxicated or in an acute withdrawal state; Currently pregnant or planning to become pregnant; Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit; Has had ECT treatment within the last 6 months
- Inclusion and exclusion criteria for Group 5: Healthy Volunteers; Inclusion criteria for Group 5:; Male or female, age 18 or older; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Physically healthy as determined by research psychiatrist; Without any current and/or lifetime psychiatric disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI); Exclusion Criteria for Group 5:; Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any psychiatric disorder including any severe personality disorder; Currently pregnant or planning to become pregnant; Tests positive for illegal substances or prescription medications for which they do not have a valid prescription; Currently taking any steroids, stimulants, or opioid pain killers; Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit
Helyszínek itt: Egyesült Államok
- University Hospitals Cleveland Medical Center - Mood Disorders ProgramCleveland, Egyesült ÁllamokContact: Nicole Jones, MARésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to use eye-tracking technology to study attentional biases, reward sensitivity, and cognitive control in adult patients with bipolar disorder with or without anxiety and/or substance use disorder comorbidity.
A vizsgálat 5 csoportja
- Bipolar without Anxiety or Substance Use Disorder
Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
Kezelés: Eye tracking
- Bipolar disorder with a current anxiety disorder only
Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
Kezelés: Eye tracking
- Bipolar disorder with a current anxiety disorder and a current
Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
Kezelés: Eye tracking
- Bipolar disorder with a current substance use disorder only
Subjects who are diagnosed with bipolar disorder \& a substance use disorders but not a current anxiety disorder
Kezelés: Eye tracking
- Healthy Volunteers
Kezelés: Eye tracking
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder and Different Psychiatric Comorbidities: An Eye-Tracking Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2026. október 9.